Project Grant R01CA312142
Award Date 8/12/26
Completion Date 7/31/31
Dollars Obligated $738K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $181,610 on September 1, 2026, to develop and deploy computational methods for creating novel immunotherapies targeting neuroblastoma in children under the Cancer Treatment Research program (CFDA 93.395). The funded work centers on bioinformatics pipeline development and analysis of proteogenomic data to identify new immunotherapeutic targets for pediatric cancer. Under the leadership of Dr. John Maris and...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded $457,683 to The Children's Hospital of Philadelphia on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize a macromolecular prodrug-based delivery strategy for the topoisomerase I inhibitor SN22 designed to overcome tumor defense mechanisms and suppress high-risk neuroblastoma, the most common and deadly solid tumor of childhood. The project targets...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $350,860 on September 1, 2026, through a Cooperative Agreement (UH2CA312695) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to implement exome capture-based RNA sequencing for real-time clinical risk stratification in pediatric B-cell acute lymphoblastic leukemia (B-ALL) treatment. The recipient will establish centralized diagnostic RNA sequencing-based molecular classification across three...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $197,518 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective September 8, 2025, through August 31, 2030. This award supports the development of a Rare Tumor Clinical Research Specialist position focused on addressing critical barriers in clinical research for rare cancers, which collectively account for 25% of cancer deaths despite...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia Research Institute $276,545 on June 8, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop genomic risk prediction models for T-cell malignancies. The recipient will identify high-risk genomic features associated with relapse and death in T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) stratified by genetic ancestry, then develop and validate risk prediction...
- The National Cancer Institute awarded The Children's Hospital Of Philadelphia $744,511 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize hematopoietic stem and progenitor cell-like (HSPC-like) blasts in high-risk acute leukemias and identify therapeutic vulnerabilities in these treatment-resistant leukemic populations. The research investigates molecular characteristics and clinical implications of HSPC-like blasts across major high-risk leukemia...
- Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia a $427,064 cooperative agreement on July 16, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to generate pilot and feasibility data for a planned randomized controlled trial evaluating circulating tumor DNA (ctDNA) screening in individuals with Li-Fraumeni syndrome. The award funds development of pilot and feasibility protocols that will precede a larger national trial assessing the...
- The National Cancer Institute awarded the University of Pennsylvania $100,228 on January 27, 2027, under the Cancer Research Manpower program (CFDA 93.398) to develop a pediatric pathology foundation model for morphological and epigenetic biomarker discovery in childhood cancers. The project will build the first pan-cancer pediatric pathology foundation model using more than 800,000 whole-slide images from approximately 70,000 pediatric patients at the Children's Hospital of Philadelphia, then...
- The National Institutes of Health National Cancer Institute awarded the University of Illinois $544,520 on April 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a microRNA-based therapeutic approach for pediatric high-grade gliomas. The project develops a cell-penetrating peptide-conjugated antisense-microRNA20a therapeutic agent (AMIR20-P28) designed to target oncogenic microRNA expression in pediatric primary high-grade gliomas, including pediatric glioblastomas...